精优药业年报2025

2025ANNUAL REPORT Corporate InformationChairman’s StatementManagement Discussion and AnalysisDirectors and Senior Management ProfileCorporate Governance ReportEnvironmental, Social and Governance ReportReport of the DirectorsIndependent Auditor’s ReportConsolidated Financial StatementsConsolidated Statement of Profit or Loss andOther Comprehensive IncomeConsolidated Statement of Financial PositionConsolidated Statement of Changes in EquityConsolidated Statement of Cash FlowsNotes to the Consolidated Financial StatementsFive Years’ Financial Summary02040822274976899698100102104220 CONTENTS目錄 CORPORATE INFORMATION公司資料EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED精優藥業控股有限公司02BOARD OF DIRECTORSExecutive DirectorsDr. XIE Yi(Chairman and Chief Executive Officer)Mr. CHENG Yong(Deputy Chief Executive Officer)Dr. LOU YiMs. WONG Sau KuenDr. GUO YiIndependent Non-executive DirectorsMr. FANG Lin HuMs. JIN SongDr. ZENG LiAUDIT COMMITTEEMr. FANG Lin Hu(Chairman)Ms. JIN SongDr. ZENG LIREMUNERATION COMMITTEEMr. FANG Lin Hu(Chairman)Ms. JIN SongDr. ZENG LIDr. XIE YiNOMINATION COMMITTEEDr. XIE Yi(Chairman)Mr. FANG Lin HuMs. JIN SongDr. ZENG LiCOMPANY SECRETARYMs. WONG Sau KuenHONG KONG LEGAL ADVISERSChiu & Partners SolicitorsINDEPENDENT AUDITORSFAI (HK) CPA LimitedCertified Public Accountants • ANNUAL REPORT 2025二零二五年年報CORPORATE INFORMATION (CONTINUED)公司資料（續）REGISTERED OFFICEClarendon House2 Church StreetHamilton HM 11BermudaHEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS IN HONG KONGSuites 2206–08, 22/FDevon House, Taikoo Place979 King’s RoadQuarry BayHong KongPRINCIPAL BANKERSIndustrial and Commercial Bank of China (Asia) LimitedThe Bank of East Asia, LimitedPRINCIPAL SHARE REGISTRAR ANDTRANSFER OFFICEConyers Corporate Services (Bermuda) LimitedClarendon House, 2 Church StreetHamilton HM 11BermudaHONG KONG BRANCH SHARE REGISTRARAND TRANSFER OFFICETricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong KongWEBSITEhttp://www.extrawell.com.hkSTOCK CODEThe Stock Exchange of Hong Kong Limited: 00858Clarendon House2 Church StreetHamilton HM 11Bermuda97922Conyers Corporate Services (Bermuda) LimitedClarendon House, 2 Church StreetHamilton HM 11Bermuda1617http://www.extrawell.com.hk 2206–08 00858 03 CHAIRMAN’SSTATEMENT主席報告04Dear Shareholders:On behalf of the board ofdirectors (the “Board”) ofExtrawell PharmaceuticalHoldings Limited (the“Company”, together with itssubsidiaries, the “Group”), I ampleased to present the annualreport of the Group for the yearended 31 March 2025. CHAIRMAN’S STATEMENT (CONTINUED)主席報告（續）The global economic outlook is clouded by the rising uncertainty amidthe escalation of potential trade conflicts and ongoing geopoliticaltensions. The global trade landscape has witnessed shifts drivenbyescalating tariffs,geopolitical realignments,and supply chaindisruptions, leading to increased cost fluctuations while introducingnew complexities and challenges.Despite multiple external headwinds, China’s economy acceleratedto 5.4% growth year-on-year in the fourth quarter of 2024, liftingfull year growth to 5.0%, and maintained the same pace of growthat 5.4% in the first quarter of 2025. The economic achievementsprovide a solid foundation for achieving goals outlined in the nation’s14thFive-Year Plan(2021–2025).China is undergoing structuraltransformation which is progressing through high-quality developmentanddeepened economic reforms,and shifting toward a modelpowered by domestic demand and innovation. Meanwhile, China’spharmaceutical industry is undergoing continuous transformation andupgrading guided by the national policies. The combined factors ofthe shifting demographics, evolving healthcare needs and regulatoryreforms are reshaping China’s pharmaceutical industry landscape.The pharmaceutical industry has continued to maintain its growthmomentum driven by the increasing burden of the nation’s agingpopulation and chronic diseases and a surge for demand for qualitydrugs to meet the evolving needs of patients. The impacts of theongoingimplementation of medical insurance cost-control policyand the national centralised procurement policy increase operatingcomplexitiesfor businesses amid fierce competition.However,China’spharmaceutical industry has demonstrated a high-qualitydevelopmentmomentum driven by policy support,technologicalinnovationand market demand,creating new opportunities andexpectations for businesses. ANNUAL REPORT 2025二零二五年年報055.4%5.0%5.4% EXTRAWELL PHARMACEUTICAL HOLDINGS LIMITED精優藥業控股有限公司06CHAIRMAN’S STATEMENT (CONTINUED)主席報告（續）Thenumerous challenges from changes in industry policies andregulations, adjustments of market demand structure and pressureonprofit margins continue to heighten operational complexitiesduring the industry transformation cycle. The Group has intensifiedits efforts in strengthening its internal management in order to timelyrespond to such challenges and changes, and has endeavored toalign its development direction with national strategies and policyf